Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseases

Department of Internal Medicine and Sistemic Diseases, University of Catania, Italy.
World Journal of Gastroenterology (Impact Factor: 2.37). 05/2004; 10(9):1353-6.
Source: PubMed


To investigate the serum erythropoietin (Epo) levels in patients with chronic liver diseases and to compare to subjects with iron-deficiency anaemia and healthy controls.
We examined 31 anaemic (ALC) and 22 non-anaemic (NALC) cirrhotic patients, 21 non- anaemic subjects with chronic active hepatitis (CAH), 24 patients with iron-deficiency anaemia (ID) and 15 healthy controls. Circulating Epo levels (ELISA; R and D Systems, Europe Ltd, Abingdon, UK) and haemoglobin (Hb) concentration were determined in all subjects.
Mean+/-SD of Epo values was 26.9+/-10.8 mU/mL in ALC patients, 12.5+/-8.0 mU/mL in NALC subjects, 11.6+/-6.3 mU/mL in CAH patients, 56.4+/-12.7 mU/mL in the cases of ID and 9.3+/-2.6 mU/mL in controls. No significant difference (P>0.05) was found in Epo levels between controls, CAH and NALC patients. ALC individuals had higher Epo levels (P<0.01) than these groups whereas ID subjects had even higher levels (P<0.001) than patients suffering from ALC.
Increased Epo values in cirrhotics, are only detectable when haemoglobin was lesser than 12 g/dL. Nevertheless, this rise in value is lower than that observed in anaemic patients with iron-deficiency and appears blunted and inadequate in comparison to the degree of anaemia.

Download full-text


Available from: Rinaldo Pellicano,
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of our study was to investigate circulating levels of intercellular adhesion molecule-1 (sICAM-1) and vascular cellular adhesion molecule-1 (sVCAM-1) in cirrhotic patients, with and without chronic anaemia, to establish whether there was a relationship between inflammatory activity and anaemia. We investigated 14 anaemic (mean hemoglobin value 10.65+/-1.06 g/dL) and 14 non anaemic (mean hemoglobin value 13.8+/-0.89 g/dL) subjects affected by virus C-related liver cirrhosis comparable for sex, age and degree of liver dysfunction such as expressed by Child-Pugh classification. Circulating sICAM-1 and sVCAM-1 were measured by EIA commercial kit (R&D System Co, Abington, UK) and mean+/- standard deviation values in two groups were compared by t-test and Kruskall-Wallis test. Mean+/-standard deviation sICAM-1 was 35.06+/-4.06 ng/mL in anaemic and 23.39+/- 6.1 ng/mL in non anaemic cirrhotic patients. Mean+/-standard deviation sVCAM-1 was 47.66+/-8.18 ng/mL in anaemic 31.77+/-6.08 ng/mL in non anaemic patients, respectively. Statistical analysis showed a significant difference between the two groups both in sICAM-1 (p=0.01) and sVCAM-1 (p=0.03) values. Our study show that chronic anaemia, in liver cirrhosis, is associated to a greater increase of circulating adhesion molecules and suggests that inflammation may contribute to persistence of anaemic state, worsening the outcome of cirrhotic patients.
    Minerva gastroenterologica e dietologica 06/2005; 51(2):187-91.
  • Source

    World Journal of Gastroenterology 07/2005; 11(23):3649. · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interferon (IFN)-based regimens for the treatment of chronic hepatitis C virus (HCV) infection have become increasingly effective and are able to eradicate virus in more than one half of treated individuals. Treatment strategies are complex and involve self-administration of injectable IFN and oral ribavirin medication, frequent office visits, and laboratory testing. Current therapies have significant side effects that may impair performance and quality of life (QOL), necessitating dose reductions or interruption of therapy. As a consequence of these dose reductions or treatment interruptions, patients may not achieve a sustained virologic response (SVR). Recent data suggest that aggressive management of side effects may improve QOL and therefore patient adherence to therapy. Use of antidepressant and anxiolytic medications and off-label use of hemopoietic stem cell growth factors are increasing in the daily management of HCV therapy. Although these therapies may improve QOL, prevent dose reductions, and increase the number of patients completing therapy, there are no data available to definitively show that such tactics are associated with improvement in SVR rates in individual patients.
    Clinics in Liver Disease 09/2005; 9(3):439-51, vii. DOI:10.1016/j.cld.2005.05.012 · 3.66 Impact Factor
Show more